Substance Use Disorders Medication-Assisted Treatment

Substance use disorders (SUDs) continue to pose a significant public health challenge, affecting millions of individuals and families across the United States. The increasing prevalence of opioid use disorder (OUD), alcohol use disorder (AUD), and nicotine addiction demands comprehensive and evidence-based treatment strategies. This CE course is explicitly designed for Nurses and Nurse Practitioners (NPs) to provide an in-depth understanding of Medication-Assisted Treatment (MAT) as a cornerstone for addressing SUDs. Participants will learn to identify clinical presentations and diagnostic criteria for SUD, and how to apply MAT effectively across different substance use disorders.

The course covers the pharmacology, mechanisms of action, indications, contraindications, and side effects of key medications used in the treatment of OUD and AUD. This includes drugs such as methadone, buprenorphine, naltrexone, disulfiram, acamprosate, and topiramate. Emphasis is placed on tailoring therapy for special populations such as pregnant or lactating women and the elderly. Learners will also explore strategies to promote adherence, manage adverse effects, and integrate psychosocial interventions alongside pharmacotherapy.

By completing this course, healthcare professionals will be equipped with the knowledge and tools needed to deliver compassionate, patient-centered, and effective care for individuals living with substance use disorders, ultimately leading to better treatment outcomes and reduced relapse rates.

EDUCATIONAL OBJECTIVES

• Define the scope and various types of substance use disorders (SUD), including opioid use disorder (OUD), alcohol use disorder (AUD), and nicotine addiction.
• Identify diagnostic criteria and common clinical signs associated with SUD.
• Explain the role of medication-assisted treatment (MAT) in conjunction with behavioral therapies.
• Review the mechanisms of action, uses, and safety profiles of medications used to treat AUD (e.g., naltrexone, acamprosate, disulfiram, topiramate).
• Analyze pharmacological agents used in the treatment of OUD, such as methadone, buprenorphine, and naltrexone, including their pharmacokinetics and contraindications.
• Describe how to monitor patients on MAT, including identifying and managing common and severe side effects.
• Develop patient education strategies to encourage treatment adherence and lifestyle changes.
• Recognize special considerations when treating specific populations (e.g., pregnant women, the elderly).
• Utilize evidence-based guidelines to select and administer MAT appropriately.
• Implement a multidisciplinary care model to enhance patient safety, support, and outcomes in SUD treatment.

WHO SHOULD DO THIS COURSE

This course is essential for Registered Nurses (RNs) and Nurse Practitioners (NPs) involved in managing patients with substance use disorders. It is particularly relevant for those seeking to fulfill their state-mandated CE license renewal requirements in the following categories:

• Substance Use Disorder: Nurses licensed in Massachusetts, Rhode Island, West Virginia, Arizona, and Indiana.
• Advanced Pharmacology: Nurses licensed in Ohio and Alaska.
• Pharmacotherapeutics: Nurses licensed in Hawaii, Louisiana, Oklahoma, West Virginia, Connecticut, Arkansas, Illinois, Nebraska, South Carolina, Texas, Washington, and Wisconsin.
• Pharmacology: Nurses licensed in Alabama and Indiana.

Healthcare providers practicing in primary care, behavioral health, addiction treatment, and pain management settings will also benefit greatly from the course content.

DID YOU KNOW?

• According to the CDC, more than 100,000 Americans died from drug overdoses in 2022, with opioids involved in over 75% of these deaths.
• MAT has been shown to reduce opioid use, increase patient retention in treatment, and decrease the risk of fatal overdose by up to 50%.
• Only 11% of people with substance use disorder receive the treatment they need, underscoring the importance of expanding access to trained providers.
• Buprenorphine and methadone are on the World Health Organization’s list of essential medications for the treatment of opioid use disorder.